Prefer Cipla: Rajesh Kothari

Rajesh Kothari - Managing Director at AlfAccurate Advisors told CNBC-TV18, "We are holding Cipla in our portfolio, of course today’s announcement with reference to equity share, I think the management claims that it is going to be earning per share (EPS) accretive. We need to still do lot of work on the recent acquisition policy. However, whatever is important, I think these entire healthcare as well as software sector are surely going to continue to outperform probably over at least next three to six months because there is a very strong earnings growth in few of these largecap names and that provides very good opportunity." "From the market perspective if you look at it, there are few strong domestic plays and now even the export sector pharmaceutical and software is going to join from the valuation perspective as well as the earnings growth perspective. So from market perspective we believe that probably this is a good correction and one should use volatility to your advantage and keep building on every dip. So, it is going to remain volatile for at least next 10-15 days. It is a consensus call in the market. However, what is important is how you use this volatility to your advantage to build your long-term portfolios," he said.